Cargando…
Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro
The initiation of cell-mediated immunity to Epstein-Barr virus (EBV) has been analyzed with cells from EBV-seronegative blood donors in culture. The addition of dendritic cells (DCs) is essential to prime naive T cells that recognize EBV-latent antigens in enzyme-linked immunospot assays for interfe...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194129/ https://www.ncbi.nlm.nih.gov/pubmed/14657218 http://dx.doi.org/10.1084/jem.20030646 |
_version_ | 1782147632781590528 |
---|---|
author | Bickham, Kara Goodman, Kiera Paludan, Casper Nikiforow, Sarah Tsang, Ming Li Steinman, Ralph M. Münz, Christian |
author_facet | Bickham, Kara Goodman, Kiera Paludan, Casper Nikiforow, Sarah Tsang, Ming Li Steinman, Ralph M. Münz, Christian |
author_sort | Bickham, Kara |
collection | PubMed |
description | The initiation of cell-mediated immunity to Epstein-Barr virus (EBV) has been analyzed with cells from EBV-seronegative blood donors in culture. The addition of dendritic cells (DCs) is essential to prime naive T cells that recognize EBV-latent antigens in enzyme-linked immunospot assays for interferon γ secretion and eradicate transformed B cells in regression assays. In contrast, DCs are not required to control the outgrowth of EBV-transformed B lymphocytes from seropositive donors. Enriched CD4(+) and CD8(+) T cells mediate regression of EBV-transformed cells in seronegative and seropositive donors, but the kinetics of T-dependent regression occurs with much greater speed with seropositives. EBV infection of DCs cannot be detected by reverse transcription–polymerase chain reaction with primers specific for mRNA for the EBNA1 U and K exons. Instead, DCs capture B cell debris and generate T cells specific for EBV latency antigens. We suggest that the cross-presentation of EBV-latent antigens from infected B cells by DCs is required for the initiation of EBV-specific immune control in vivo and that future EBV vaccine strategies should target viral antigens to DCs. |
format | Text |
id | pubmed-2194129 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-21941292008-04-11 Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro Bickham, Kara Goodman, Kiera Paludan, Casper Nikiforow, Sarah Tsang, Ming Li Steinman, Ralph M. Münz, Christian J Exp Med Article The initiation of cell-mediated immunity to Epstein-Barr virus (EBV) has been analyzed with cells from EBV-seronegative blood donors in culture. The addition of dendritic cells (DCs) is essential to prime naive T cells that recognize EBV-latent antigens in enzyme-linked immunospot assays for interferon γ secretion and eradicate transformed B cells in regression assays. In contrast, DCs are not required to control the outgrowth of EBV-transformed B lymphocytes from seropositive donors. Enriched CD4(+) and CD8(+) T cells mediate regression of EBV-transformed cells in seronegative and seropositive donors, but the kinetics of T-dependent regression occurs with much greater speed with seropositives. EBV infection of DCs cannot be detected by reverse transcription–polymerase chain reaction with primers specific for mRNA for the EBNA1 U and K exons. Instead, DCs capture B cell debris and generate T cells specific for EBV latency antigens. We suggest that the cross-presentation of EBV-latent antigens from infected B cells by DCs is required for the initiation of EBV-specific immune control in vivo and that future EBV vaccine strategies should target viral antigens to DCs. The Rockefeller University Press 2003-12-01 /pmc/articles/PMC2194129/ /pubmed/14657218 http://dx.doi.org/10.1084/jem.20030646 Text en Copyright © 2003, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Article Bickham, Kara Goodman, Kiera Paludan, Casper Nikiforow, Sarah Tsang, Ming Li Steinman, Ralph M. Münz, Christian Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro |
title | Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro |
title_full | Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro |
title_fullStr | Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro |
title_full_unstemmed | Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro |
title_short | Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro |
title_sort | dendritic cells initiate immune control of epstein-barr virus transformation of b lymphocytes in vitro |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194129/ https://www.ncbi.nlm.nih.gov/pubmed/14657218 http://dx.doi.org/10.1084/jem.20030646 |
work_keys_str_mv | AT bickhamkara dendriticcellsinitiateimmunecontrolofepsteinbarrvirustransformationofblymphocytesinvitro AT goodmankiera dendriticcellsinitiateimmunecontrolofepsteinbarrvirustransformationofblymphocytesinvitro AT paludancasper dendriticcellsinitiateimmunecontrolofepsteinbarrvirustransformationofblymphocytesinvitro AT nikiforowsarah dendriticcellsinitiateimmunecontrolofepsteinbarrvirustransformationofblymphocytesinvitro AT tsangmingli dendriticcellsinitiateimmunecontrolofepsteinbarrvirustransformationofblymphocytesinvitro AT steinmanralphm dendriticcellsinitiateimmunecontrolofepsteinbarrvirustransformationofblymphocytesinvitro AT munzchristian dendriticcellsinitiateimmunecontrolofepsteinbarrvirustransformationofblymphocytesinvitro |